AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
TAE Life Sciences and AIVITA Biomedical Announce Strategic Partnership to Advance Development of Target Boron Drugs for Glioblastoma
AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy Congress
TAE Life Sciences and AIVITA Biomedical Announce Strategic Partnership to Advance Development of Target Boron Drugs for Glioblastoma
AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy Congress
